Homoeopathic Treatment of Mild Cases of COVID-19 on Home Isolation: A Retrospective Observational Study

Abstract

While the world grappled with the pandemic of coronavirus disease 2019 (COVID-19), medical fraternity and policy makers tried desperately to control its spread in the absence of any definite treatment protocol. The scope of homoeopathy, which has been historically found effective in epidemics, has been investigated in the present study. This study was conducted to evaluate the effect of individualised homoeopathic medicine on mild cases of COVID-19 under home isolation. A retrospective, single-arm, non-randomised, open-label, observational trial was conducted on 185 laboratory confirmed mild cases of COVID-19 at Nehru Homoeopathic Medical College and Hospital, Delhi, during September to December 2020. Complete symptom resolution days was the primary outcome (from baseline to total zero symptom score); while assessment of severity of each symptom and sign on a scale of 0-3 ( 0- absent, 1-mild. 3- severe), at baseline and Day 14 comprised of the secondary outcome. Intention-to-treat sample (n = 185) was analysed with SPSS IBM version 20. Of all the patients (n = 185), 165 (90%) successfully completed the follow-up period. The mean (interquartile range [IQR]) age was 35 (26–45) years; the male: female ratio was 11:9.2. Fever (56%), cough (54%), fatigue (45%) and sore throat (36%) were the most common symptoms reported. Median (IQR) time for resolution of symptoms was 4 (3–8) days. Sixty-eight per cent patients recovered within 6 days and rest within 7 to 14 days. The most prescribed medicines were Bryonia alba (30%), Arsenicum album (25%) and Pulsatilla nigricans (12%) accounting for 67% of the total medicines. This study, though preliminary, revealed a positive treatment effect of individualised homoeopathic medicines in promptly alleviating the symptoms of mild COVID-19. Randomised controlled trials with greater scientific rigour are warranted.

Keywords

COVID-19 - home isolation - homoeopathy - symptom resolution days - Bryonia alba

Publikationsverlauf

Artikel online veröffentlicht:
09. August 2023

• References

• 1 World Health Organization. . Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020. Accessed May 9, 2023 at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
• 2 Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-98
• 3 Prajapati S, Sharma M, Kumar A, Gupta P, Narasimha Kumar GV. An update on novel COVID-19 pandemic: a battle between humans and virus. Eur Rev Med Pharmacol Sci 2020; 24 (10) 5819-5829
• 4 Huang B, Ling R, Cheng Y. et al. Characteristics of the coronavirus disease 2019 and related therapeutic options. Mol Ther Methods Clin Dev 2020; 18: 367-375
• 5 Radhakrishnan N, Gupta DK. India's COVID-19 response: science first. Lancet 2021; 397 (10293): 2464-2465
• 6 Ministry of Ayush. . Government of India. 2020. Advisory from Ministry of AYUSH for Meeting the Challenge Arising Out of Spread of Corona Virus (COVID-19) in India. Accessed May 9, 2023 at: https://www.ayush.gov.in/docs/125.pdf
• 7 Weiermayer P, Frass M, Peinbauer T, Ellinger L. [Evidence-based homeopathy and veterinary homeopathy, and its potential to help overcome the anti-microbial resistance problem - an overview]. Schweiz Arch Tierheilkd 2020; 162 (10) 597-615
• 8 Chaudhary A, Khurana A. A review on the role of Homoeopathy in epidemics with some reflections on COVID-19 (SARS-CoV-2). Indian J Res Homoeopathy 2020; 14: 100-109
• 9 Hahnemann S. . Treatment of the typhus or hospital fever at present prevailing. In: Dudgeon RE, ed. The Lesser Writings of Samuel Hahnemann. Rep ed. New Delhi: B. Jain Publishers; 1995:631–635.
• 10 Nair KR, Gopinadhan S, Sreedhara KT. et al. Homoeopathic genus epidemicus ‘Bryonia alba’ as a prophylactic during an outbreak of chikungunya in India: a cluster-randomised, double-blind, placebo-controlled trial. Indian J Res Homoeopathy 2014; 8: 160-165
• 11 Teixeira MT. Homeopathy: a preventive approach to medicine?. Int J High Dilution Res 2009; 8: 155-172
• 12 Baker WF. Research work in Gelsemium sempervirens and Bryonia alba in influenza. J Am Inst Homeopath 1920; 12: 695-698
• 13 Grimes M. . Important for Swine Flu Epidemic: Homeopathy Successfully Treated Flu Epidemic of 1918 [newspaper on the Internet]. 2009 Apr 28: [about 3 p.]. Accessed May 9, 2023 at: http://www.naturalnews.com/z026148_homeopathy_epidemic_flu_epidemic.html
• 14 Shalts E. . Consistently proven effective. In: The American Institute of Homeopathy Handbook for Parents. San Francisco: Jossey-Bass; 2005:33–40
• 15 To KLA, Fok YYY. Homeopathic clinical features of 18 patients in COVID-19 outbreaks in Hong Kong. Homeopathy 2020; 109 (03) 146-162
• 16 Vellingiri B, Jayaramayya K, Iyer M. et al. COVID-19: a promising cure for the global panic. Sci Total Environ 2020; 725: 138277
• 17 Accessed July 4, 2023 at: https://yourstory.com/2020/06/covid-19-alternative-medicine-ayurveda-industry-trends-analysis
• 18 MOHFW, Revised Home Isolation Guidelines. Accessed May 9, 2023 at: https://www.mohfw.gov.in/pdf/RevisedHomeIsolationGuidelines.pdf
• 19 Jethani B, Gupta M, Wadhwani P. et al. Clinical characteristics and remedy profiles of patients with COVID-19: a retrospective cohort study. Homeopathy 2021; 110 (02) 86-93
• 20 Manchanda RK, Miglani A, Gupta M. et al. Homeopathic remedies in COVID-19: prognostic factor research. Homeopathy 2021; 110 (03) 160-167
• 21 Manchanda RK, Miglani A, Chakraborty M. et al. Homeopathic medicines in second wave of COVID-19: prognostic factor research. Homeopathy 2023; 112 (01) 12-21
• 22 Valeri A. . Symptomatic COVID-19 positive and likely patients treated by homeopathic physicians - an Italian descriptive study. 2020. Accessed May 9, 2023 at: https://www.researchgate.net/publication/340631586_Symptomatic_COVID-19_positive_and_likely_patients_treated_by_homeopathic_physicians_an_Italian_descriptive_study
• 23 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
• 24 Guan GW, Gao L, Wang JW. et al. [Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia]. Zhonghua Gan Zang Bing Za Zhi 2020; 28 (02) 100-106
• 25 Henry BM, Vikse J. Clinical characteristics of Covid-19 in China. N Engl J Med 2020; 382 (19) 1860-1861
• 26 Eastin C, Eastin T. Clinical characteristics of coronavirus disease 2019 in China. J Emerg Med 2020; 58 (04) 711-712
• 27 Suleyman G, Fadel RA, Malette KM. et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open 2020; 3 (06) e2012270
• 28 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet 2020; 395 (10229): 1054-1062
• 29 Richardson S, Hirsch JS, Narasimhan M. et al; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. [published correction appears in JAMA. 2020 May 26;323(20):2098] JAMA 2020; 323 (20) 2052-2059
• 30 Grasselli G, Zangrillo A, Zanella A. et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. [published correction appears in JAMA. 2021 May 25;325(20):2120] JAMA 2020; 323 (16) 1574-1581
• 31 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061-1069
• 32 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-513
• 33 Hu SS, Gao RL, Liu LS. et al. Summary of the 2018 report on cardiovascular diseases in China. Chin Circ J. 2019; 34: 209-220
• 34 Liu M, Liu SW, Wang LJ. et al. Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to 2016, global burden of disease study. Diabetes Metab 2019; 45 (03) 286-293